The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Open accessAbstract
BACKGROUND: We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia. METHODS: A total of 809 patients with essential thrombocythemia who were at high risk for vascular events received low-dose aspirin plus either anagrelide or hydroxyurea. The composite primary end point was the actuarial risk of arterial thrombosis (myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or peripheral arterial thrombosis), venous thrombosis (deep-vein thrombosis, splanchnic-vein thrombosis, or pulmonary embolism), serious hemorrhage, or death from thrombotic or hemorrhagic causes. RESULTS: After a median follow-up of 39 months, patients in the anagrelide group were significantly more likely than those in the hydroxyurea group to have reached the primary end point (odds ratio, 1.57; 95 percent confidence interval, 1.04 to 2.37; P=0.03). As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0.004), serious hemorrhage (P=0.008), and transformation to myelofibrosis (P=0.01) but with a decreased rate of venous thromboembolism (P=0.006). Patients receiving anagrelide were more likely to withdraw from their assigned treatment (P<0.001). Equivalent long-term control of the platelet count was achieved in both groups. CONCLUSIONS: Hydroxyurea plus low-dose aspirin is superior to anagrelide plus low-dose aspirin for patients with essential thrombocythemia at high risk for vascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
Jaffe, E. S. (2003) · Cited by 2,141
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F., & Barbui, T. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.556 · Cited by 465
Murphy, S., Peterson, P., Iland, H., & Laszlo, J. (1997) · PubMed · Cited by 404
Sterkers, Y., Preudhomme, C., Laı̈, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 372
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O'Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 353
Cannon, C. P., McCabe, C. H., Wilcox, R. G., Langer, A., Caspi, A., Berink, P., Lopez-Sendon, J., Toman, J., Charlesworth, A., Anders, R. J., et al. (2000) · Circulation · doi:10.1161/01.cir.102.2.149 · Cited by 290
Falanga, A., Marchetti, M., Evangelista, V., Vignoli, A., Licini, M., Balicco, M., Manarini, S., Finazzi, G., Cerletti, C., & Barbui, T. (2000) · Blood · doi:10.1182/blood.v96.13.4261 · Cited by 288
Data Monitoring Committees in Clinical Trials
Ellenberg, S. S., Fleming, T. R., & DeMets, D. L. (2002) · Wiley eBooks · doi:10.1002/0470854162 · Cited by 268
Bain, B. J., Clark, D. M., Lampert, I. A., & Wilkins, B. S. (2001) · Wiley eBooks · doi:10.1002/9780470757130 · Cited by 242
Self-citationFinazzi, G., Ruggeri, M., Rodeghiero, F., & Barbui, T. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02188.x · Cited by 215
Besses, C., Cervantes, F., Pereira, A., Florensa, L., Solé, F., Hernández-Boluda, J., Woessner, S., Sans-Sabrafen, J., Rozman, C., & Montserrat, E. (1999) · Leukemia · doi:10.1038/sj.leu.2401270 · Cited by 212
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia
Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N. L., Petti, M. C., Pogliani, E., Ricetti, M., Rupoli, S., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01262.x · Cited by 202
Allocation of patients to treatment groups in a controlled clinical study
White, S. J., & Freedman, L. S. (1978) · British Journal of Cancer · doi:10.1038/bjc.1978.124 · Cited by 191
TREATMENT OF EARLY BREAST CANCER
Turnbull, A. R., Chant, A. D. B., Buchanan, R. B., Turner, D., Shepherd, J. M., & Fraser, J. D. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91320-x · Cited by 155
Chronic Myeloproliferative Disorders
Spivak, J. L., Barosi, G., Tognoni, G., Barbui, T., Finazzi, G., Marchioli, R., & Marchetti, M. (2003) · Hematology · doi:10.1182/asheducation-2003.1.200 · Cited by 155
Platelets, leukocytes, and coagulation
Bouchard, B. A., & Tracy, P. B. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200109000-00001 · Cited by 109
Tomer, A. (2002) · Blood · doi:10.1182/blood.v99.5.1602 · Cited by 97
Reversal of myelofibrosis by hydroxyurea
Löfvenberg, E., Wåhlin, A., Roos, G., et al. (1990) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1990.tb00344.x · Cited by 94
Brun, M., Bourdoulous, S., Couraud, P., Élion, J., Krishnamoorthy, R., & Lapouméroulie, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500176 · Cited by 87
Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management
Tefferi, A., & Murphy, S. (2001) · Blood Reviews · doi:10.1054/blre.2001.0158 · Cited by 87
Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea
Nahavandi, M., Tavakkoli, F., Wyche, M. Q., Perlin, E., Winter, W. P., & Castro, O. L. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03919.x · Cited by 78
Jantunen, R., Juvonen, E., Ikkala, E., Oksanen, K., Anttila, P. M., & Ruutu, T. (2001) · Annals of Hematology · doi:10.1007/s002770000244 · Cited by 65
Evaluation of diagnostic criteria in polycythemia vera
Pearson, T. C. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90136-2 · Cited by 58
Harrison, C. N., & Green, A. R. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00082-0 · Cited by 28
Self-citation
Cited by
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Self-citationBarbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationCampbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Self-citationBarbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 641
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Metadata
- Authors
- Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., Revell, P., Woodcock, B. E., & Green, A. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-07
- Volume
- 353
- Issue
- 1
- Pages
- 33-45
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2069651950
- Cited by
- 927
- References
- 28
- FWCI
- 22.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.